Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority claimed from PCT/US1998/001343external-prioritypatent/WO1998033798A2/en
Publication of NZ335666ApublicationCriticalpatent/NZ335666A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The compounds of formula I and II may be used for treating cell proliferation disorders, such as cancer and restenosis. In particular, 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. In Formula I and II; W is NH, S, SO, or SO2, X is O, S or NH, R1and R2 include heteroaryl, optionally substituted phenyl, or optionally substituted alkyl or cycloalkyl, R3 includes hydrogen or alkyl, R8 and R9 include hydrogen, alkyl, alkoxy, halo or amino, and Z is carboxy.
NZ335666A1997-02-051998-01-26Pyrido [2,3-d] pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
NZ335666A
(en)
Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
(6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis.